Citigroup set a $25.00 price objective on Alkermes (NASDAQ:ALKS) in a research note released on Friday morning, TipRanks reports. The brokerage currently has a hold rating on the stock.

A number of other analysts have also weighed in on ALKS. Piper Jaffray Companies increased their price objective on shares of Baxter International from $90.00 to $95.00 and gave the stock an overweight rating in a research note on Thursday. Zacks Investment Research upgraded shares of Hallmark Financial Services from a hold rating to a buy rating and set a $16.00 price objective on the stock in a research note on Friday, July 19th. Goldman Sachs Group reiterated a buy rating and issued a $70.00 price objective on shares of Total in a research note on Monday, July 15th. TheStreet lowered shares of Trinseo from a b- rating to a c+ rating in a research note on Friday, May 17th. Finally, ValuEngine lowered shares of Zosano Pharma from a buy rating to a hold rating in a research note on Wednesday, May 1st. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have given a buy rating to the company. The company presently has an average rating of Hold and a consensus price target of $31.70.

Shares of NASDAQ ALKS traded down $0.51 during midday trading on Friday, reaching $20.05. The company had a trading volume of 14,550 shares, compared to its average volume of 1,413,973. The company’s 50-day moving average is $22.58. The company has a market cap of $3.17 billion, a PE ratio of -286.43 and a beta of 1.83. Alkermes has a 1 year low of $20.20 and a 1 year high of $46.98. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.69 and a current ratio of 2.98.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Thursday, July 25th. The company reported ($0.06) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.20. The firm had revenue of $279.90 million for the quarter, compared to analyst estimates of $251.40 million. Alkermes had a negative net margin of 17.10% and a negative return on equity of 4.13%. The business’s quarterly revenue was down 8.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.29 earnings per share. Equities analysts expect that Alkermes will post -0.34 EPS for the current year.

In other news, Director Richard F. Pops sold 110,000 shares of Alkermes stock in a transaction dated Thursday, May 23rd. The shares were sold at an average price of $24.88, for a total value of $2,736,800.00. Following the sale, the director now owns 776,433 shares in the company, valued at $19,317,653.04. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Michael J. Landine sold 20,000 shares of Alkermes stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $24.93, for a total transaction of $498,600.00. Following the completion of the sale, the senior vice president now owns 193,426 shares in the company, valued at approximately $4,822,110.18. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 195,373 shares of company stock worth $4,905,080. 4.71% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Machina Capital S.A.S. purchased a new position in shares of Alkermes in the second quarter worth about $37,000. Pendal Group Ltd purchased a new position in shares of Alkermes in the first quarter worth about $82,000. Globeflex Capital L P purchased a new position in shares of Alkermes in the first quarter worth about $148,000. Commerce Bank purchased a new position in shares of Alkermes in the first quarter worth about $201,000. Finally, S&CO Inc. lifted its stake in shares of Alkermes by 12.2% in the second quarter. S&CO Inc. now owns 9,200 shares of the company’s stock worth $207,000 after buying an additional 1,000 shares in the last quarter. Institutional investors and hedge funds own 97.34% of the company’s stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.

Featured Story: Total Return

Analyst Recommendations for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.